Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sun Pharmaceutical Industries Ltd.
Headquarters: Mumbai, Maharshtra, India
Website: http://www.sunpharma.com
Year Founded: 1983
Status: Public
Industry Sector: HealthTechnology
CEO: Dilip Shantilal Shanghvi
Number Of Employees: 25,894
Enterprise Value: $45,143,266,152
PE Ratio: 35.33
Exchange/Ticker 1: NSE:SUNPHARMA
Exchange/Ticker 2: BSE:524715
Latest Market Cap: $46,395,299,788
BioCentury | Mar 10, 2025
Deals
Sun takes shine to Checkpoint in $355M buyout: Deals Report
Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum
BioCentury | Aug 13, 2024
Data Byte
Summer lull as FDA approves only 2 NMEs in July
Total for the year stands at 26, lagging last year
BioCentury | May 6, 2024
Management Tracks
Pfizer taps Citi’s Baum for C-level pipeline management and strategy role
Plus: Radiotherapy play Ratio gets new COO, CFO; and updates from Araceli, Kezar and Hercules
BioCentury | Apr 6, 2024
Finance
Public equity report: Contineum’s NASDAQ listing, Oruka’s financing-merger combo
Plus: Surrozen and Sutro raise cash, and Redx proposes to delist from London’s AIM
BioCentury | Jan 23, 2024
Deals
Deals roundup: Coherus sharpens oncology focus, BridgeBio bolsters balance sheet and more
BioCentury’s weekly roundup of biopharma deals, Jan. 16-22
BioCentury | Dec 23, 2023
Regulation
Dec. 22 Quick Takes: Sarepta seeking expanded label, full approval of DMD gene therapy
Plus: June PDUFA date for Daiichi-Merck ADC, and updates from Lyndra, ImpriMed, Mundipharma and Novamab
BioCentury | Jan 19, 2023
Deals
Building dermatology franchise, Sun buys Concert in latest CVR deal
With cash running short, 17-year-old Concert accepts offer for $576M up front as it finally neared commercial stage
BioCentury | Jul 27, 2022
Deals
July 26 Quick Takes: Merck, Kelun enter second development deal
Plus BridgeBio falls after achondroplasia Phase II data and updates from AbbVie, Aurinia and CEPI
BioCentury | May 18, 2022
Management Tracks
Fromen to leave PacBio as CCO
Plus Vraniak joins Inversago as CFO and updates from Thabor, Glympse, Civetta and more
Items per page:
1 - 10 of 123